Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Novel biomarkers in pulmonary hypertension: therapeutic implications nowadays?

8 views

Published on

Novel biomarkers in pulmonary hypertension: therapeutic implications nowadays?

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Novel biomarkers in pulmonary hypertension: therapeutic implications nowadays?

  1. 1. Dr. Diego A. Rodríguez MD, PhD. Pulmonary Hypertension Unit and Pulmonary Embolism Response Team, Pulmonology Department, Hospital del Mar, Barcelona. darodriguez@psmar.cat Novel biomarkers in pulmonary hypertension: therapeutic implications nowadays?
  2. 2. SCHEMATIC DIAGRAM SHOWING DIFFERENT GROUPS OF BIOMARKERS FOR PULMONARY HYPERTENSION
  3. 3. BIOMARKERS FOR A SAME DISEASE (?) Eur Respir J 2012; 40: 596–603 Eur Respir J. 2019 Jan 24;53(1).
  4. 4. COMPARISON AMONG MAIN FEATURES OF BIOMARKERS THAT MAY INFLUENCE THEIR USE IN CLINICAL PRACTICE
  5. 5. BIOMARKER CORRELATIONS WITH CLINICAL ENDPOINTS AND PROGNOSIS IN PULMONARY HYPERTENSION Biomarker signatures that might predict favorable responses to therapies. 0 Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015
  6. 6. TREATMENT-RELATED BIOMARKER CHANGES IN PULMONARY HYPERTENSION Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015
  7. 7. CLINICAL TRIALS EVALUATING NT-PROBNP AS A BIOMARKER FOR PULMONARY ARTERIAL HYPERTENSION COMBINATION THERAPY Am J Cardiol 2017;120:S89–S95
  8. 8. BIOMARKERS (No, Thanks) Eur Respir J. 2019 Jan 24;53(1)
  9. 9. RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION 2015 ESC/ERS Guidelines
  10. 10. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension Eur Respir J. 2017 Aug 3;50(2) Kidney Function Obesity Age
  11. 11. THE BEST BIOMARKER !!!! (2019 “up-date”) Eur Respir J 2018; 52: 1800497
  12. 12. THE BEST BIOMARKER !!!! (2019 “up-date”) Advances in Pulmonary Hypertension Volume 16, Number 3; 2018
  13. 13. DYSPNEA, THE GREAT UNKNOWN ... Eur Respir J. 2019 Jan 24;53(1).
  14. 14. Vasoregulatory mediators and/or biomarkers relevant to current pulmonary arterial hypertension (PAH) therapy, and their interactions. Am J Respir Cell Mol Biol Vol 52, Iss 6, pp 663–673, Jun 2015 Endothelial cells vascular smooth muscle cells Endogenous mediators Enzymes or other protein targets Mediator-relevant drugs (stimulatory) Mediator-relevant drugs (inhibitory])
  15. 15. CONCLUSIONS • There is no single biomarker in PH that shows superiority in predicting patient response. • An integrative approach is necessary, using a combination of biomarkers along with other clinical and paraclinical tests like NYHA functional class and echocardiography. • The identification of novel biomarker is urgently needed to help optimize and individualize therapy.
  16. 16. Dr. Diego A. Rodríguez MD, PhD. Pulmonary Hypertension Unit and Pulmonary Embolism Response Team, Pulmonology Department, Hospital del Mar, Barcelona. darodriguez@psmar.cat Novel biomarkers in pulmonary hypertension: therapeutic implications nowadays?

×